AstraZeneca (LSE:AZN) and Daiichi Sankyo (USOTC:DSKYF) have entered a clinical collaboration with Summit Therapeutics (NASDAQ:SMMT) to evaluate Datroway in combination with ivonescimab across multiple tumour types.
The programme is expected to begin with a Phase III trial assessing the combination as a first-line treatment for triple-negative breast cancer.
Datroway is a TROP2-directed antibody drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo, while ivonescimab is Summit Therapeutics’ bispecific antibody targeting PD-1 and VEGF.
Under the agreement, the companies will each supply their respective medicines and share the costs associated with the clinical trials. Each party will retain its existing development and commercial rights to its respective treatment.
The agreement expands AstraZeneca’s existing clinical collaboration with Summit involving combinations of antibody drug conjugates and ivonescimab. That collaboration includes Datroway, sonesitatug vedotin and potential additional ADC-based combinations.
AstraZeneca has also made an equity investment connected with its clinical collaboration with Summit.
The companies intend to evaluate the Datroway and ivonescimab combination in several solid tumour settings. The trials will determine the safety and efficacy of using the two treatments together.
About the Companies and Treatments
AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, UK, with operations across oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology medicines.
Daiichi Sankyo works with AstraZeneca on several DXd antibody drug conjugates, including Datroway and Enhertu, under global collaboration agreements covering most markets outside Japan.
Summit Therapeutics is developing ivonescimab as a bispecific PD-1/VEGF antibody across several solid tumour indications. The treatment is approved in China for certain patients with non-small cell lung cancer and, according to the source material, is under regulatory review in the US.
Leave a Reply